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ARTICLE
Clinically compliant spatial and temporal imaging of
chimeric antigen receptor T-cells
Nia Emami-Shahri1, Julie Foster2, Roxana Kashani2, Patrycja Gazinska3, Celia Cook1, Jane Sosabowski2,
John Maher4,5,6 & Sophie Papa 1,7
The unprecedented efﬁcacy of chimeric antigen receptor (CAR) T-cell immunotherapy of
CD19+ B-cell malignancy has established a new therapeutic pillar of hematology–oncology.
Nonetheless, formidable challenges remain for the attainment of comparable success in
patients with solid tumors. To accelerate progress and rapidly characterize emerging toxi-
cities, systems that permit the repeated and non-invasive assessment of CAR T-cell bio-
distribution would be invaluable. An ideal solution would entail the use of a non-immunogenic
reporter that mediates speciﬁc uptake of an inexpensive, non-toxic and clinically established
imaging tracer by CAR T cells. Here we show the utility of the human sodium iodide sym-
porter (hNIS) for the temporal and spatial monitoring of CAR T-cell behavior in a cancer-
bearing host. This system provides a clinically compliant toolkit for high-resolution serial
imaging of CAR T cells in vivo, addressing a fundamental unmet need for future clinical
development in the ﬁeld.
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Chimeric antigen receptors are genetically delivered fusionmolecules that couple the binding of a native tumor-associated cell surface target to delivery of a bespoke T-cell
activating signal1,2. Efﬁcient disease control by CAR T cells has
been demonstrated in pre-clinical models representative of a
broad range of cancer types1,3–9. Unprecedented clinical impact
has been achieved in patients with refractory B-cell malig-
nancies10–14, with complete remissions in heavily pre-treated
patients highlighting the truly groundbreaking nature of this
advance. Some patients do not gain beneﬁt from CD19-targeted
CAR T-cell therapy, exhibiting primary resistance. Appreciation
of the frequency of disease relapse, either with CD19-positive or
CD19-negative disease, is growing as more clinical experience is
gained in CD19 expressing hematological malignancies13.
Moreover, patients may endure severe side effects due to cytokine
release syndrome (CRS), neurotoxicity, or on-target off-tumor
toxicity that is frequently unanticipated prior to ﬁrst in man
evaluation15,16. The next anticipated breakthrough is the
demonstration of meaningful efﬁcacy of CAR T-cell immu-
notherapy in patients with solid tumors. This will require that
CAR T cells can migrate to, penetrate and then persist in an active
state within a tumor microenvironment that is profoundly
immunosuppressive8,11,12,14,17–21. Given these considerations,
pre-clinical and early clinical development of novel CAR T-cell
therapies would be greatly facilitated if we could undertake
repeated and reliable tracking of these cells after their infusion in
animal studies and patients. An ideal approach would be non-
invasive, cost-efﬁcient and equally compatible with both small
animal and clinical imaging modalities22.
Single-photon emission-computed tomography (SPECT/CT)
tracking of indium-111 (111In) labeled CAR T cells provides a
brief snapshot of the fate of adoptively transferred cells
in vivo23,24. This approach gives good image resolution but is
hampered by key limitations. First, due to isotope decay, signal is
lost within 96 h. Second, labeling is agnostic to CAR expression
by T cells. Thirdly, passive labeling does not report on cellular
proliferation following adoptive transfer as signal is not main-
tained in daughter cells and, ﬁnally, activity may be mis-
registered through phagocytosis of dying labeled cells. Co-
expression of a CAR and a reporter gene within the same cell
can overcome these limitations. Proof of concept was ﬁrst
demonstrated using the herpes simplex virus thymidine kinase 1
(HSV1tk) reporter, co-expressed with a CAR and luciferase
reporter. This system enabled the serial imaging of CAR T cells
using both positron emission tomography (PET) and biolumi-
nescence imaging (BLI)25. More recently, PET imaging of
HSV1tk+ CAR T cells has been achieved in patients with high-
grade glioma26. However, HSV1tk is a viral protein which is
immunogenic in man, favoring immune-mediated recognition
and elimination of HSV1tk transduced T cells27. Use of a human
reporter gene, such as norepinephrine receptor or hNIS, would
overcome this concern28,29. As yet however, neither has been
successfully adapted to achieve real-time imaging of CAR T cells.
The somatostatin receptor type 2 (SSTR2) has been recently co-
expressed with an intracellular adhesion molecule-1 directed CAR
and imaged by PET-CT with gallium-68-labeled octreotide analog
(68Ga-DOTATOC)30,31. However, this approach has two limita-
tions. Firstly, the SSTR2 receptor internalizes on interaction with
its substrates, risking poor sensitivity, especially at lower reporter
gene expressing cell density32. Secondly, SSTR2 is expressed on
T cells and other immune cells33, accounting for the ability of
octreotide analogs and their radiolabeled derivatives to inhibit T-
cell function34. This is clearly undesirable for a broadly applicable
strategy to image therapeutic T-cell products in cancer patients.
The hNIS gene is localized on chromosome 19p12-13.2 and
encodes a 643 amino acid glycoprotein with a molecular mass of
approximately 70–90 kDa. Cloning and sequencing of the human
NIS gene was completed twenty years ago35. The hNIS is a
member of the sodium-dependent transporter family and is a
membrane spanning protein with 13 putative transmembrane
domains, an extracellular amino-terminus and an intracellular
carboxyl-terminus. The symporter co-transports two sodium ions
with one iodide ion, capitalizing on the electrochemical potential
of the sodium gradient generated by the sodium-potassium
ATPase (Na+/K+-ATPase) pump of the plasma membrane, to
rapidly concentrate inorganic iodide within the thyroid gland.
The Na+/K+-ATPase can be blocked by ouabain as well as by the
competitive inhibitors thiocyanate and perchlorate36. This sym-
porter is naturally found in stomach, salivary glands, lactating
breast and in some thyroid cancers37. Expression of hNIS may
also be detected in some non-thyroid human cancers although, in
these circumstances, it is generally located intracellularly, rather
than on the cell surface38–40. The hNIS symporter has long been
exploited in clinical medicine owing to its ability to mediate
uptake by the thyroid gland of a variety of radioisotopes, both for
diagnostic and therapeutic applications. In the context of CAR T-
cell imaging, hNIS represents an ideal candidate reporter gene
since it is non-immunogenic, is not internalized upon substrate
uptake, and is only functional in living cells41. Furthermore, hNIS
is compatible with cheap and widely used clinical radiotracers,
notably technetium-99m pertechnetate (99mTcO4−), which is
routinely administered to patients for red blood cell imaging.
Genetically delivered hNIS has been incorporated in oncolytic
virus-based clinical trials42 and in pre-clinical studies of leukocyte
imaging29,43,44, providing important additional experience. Cog-
nizant of these attributes, we set out to evaluate the use of hNIS as
an imaging reporter for CAR T-cell immunotherapy. In a model
of CAR T-cell prostate cancer immunotherapy the inclusion of
hNIS in the retroviral vector for T-cell transduction was validated
in vitro and in vivo. Radiotracer kinetics were deﬁned in trans-
duced T cells. Finally, SPECT/CT imaging with 99mTcO4−
radiotracer over the course of CAR T-cell immunotherapy of high
and low tumor burden bearing hosts demonstrates the utility of
this approach for CAR T-cell imaging.
Results
Generation of a robust in vivo model of prostate cancer. An
essential requirement in this quest is an in vivo model that
demonstrates robust and reliable anti-tumor activity of human
CAR T cells. P28ζ is a second generation CAR that enables human
T cells to elicit potent and precisely targeted anti-tumor activity
against prostate speciﬁc membrane antigen (PSMA)-expressing
prostate cancer cells2 and derived tumors45. We developed a
highly reproducible model to demonstrate in vivo function of this
CAR using PC3-LN3 (PL) prostate cancer cells. Since PL tumor
cells lack PSMA, they were engineered to co-express ﬁreﬂy luci-
ferase and tdTomato-red-ﬂuorescent protein alone (PL), or toge-
ther with PSMA (PLP; Fig. 1a). Ectopic expression of PSMA did
not alter growth kinetics in vitro (Fig. 1b), but in vivo after sub-
cutaneous (s.c.) inoculation the expression of PSMA leads to a
moderately more aggressive phenotype (Fig. 1c). Importantly
tumor cells did not express hNIS (Fig. 1d) and consequently did
not exhibit in vitro 99mTcO4− uptake (Fig. 1e). When propagated
as s.c. xenografts, in NOD-SCID-Gamma mice (NSG), tumors
progressed rapidly and in a highly reproducible manner through
low (7 days) and high burden stages (day 14). Animals were
humanely killed at or soon after day 21, due to large tumor size
and/or impending ulceration.
Co-expression of hNIS in CAR retroviral constructs. Tri-
cistronic retroviral vectors were constructed to co-express P28ζ or
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a matched control CAR, truncated from the intracellular domain
of CD28 (PTr); an interleukin (IL)-4 responsive chimeric cyto-
kine receptor, named 4αβ (coupling the IL-4 receptor (IL-4R) α
ectodomain to the transmembrane and endodomain of IL-2/IL-
15Rβ46); and the hNIS (giving 4P28ζN or the truncated control
4PTrN, (Fig. 2a) utilizing the Thosea Asigna (T2A) ribosomal
skip peptide to achieve stoichiometric co-expression of all three
transgenes47. Expression of all transgenes was demonstrated in
retroviral packaging cell lines (Supplementary Fig. 1a) and in
retrovirus-transduced T cells by ﬂow cytometry (Fig. 2b). When
surface expression of 4αβ levels on transduced T cells was
quantiﬁed, variability was minimal between donors (Fig. 2c). Both
CD4+ and CD8+ subsets of in vitro transduced T cells showed a
predominately effector memory phenotype, accompanied by
smaller numbers of central memory cells (Supplementary Fig. 2a,
b). With the exception of one donor whose T cells were greater
than 95% CD4+ (Supplementary Fig. 2c-d), the CD4/CD8 ratio
was consistently around 2:1 for all other donors.
Functional validation of CAR efﬁcacy and speciﬁcity. Func-
tional activity of the CAR was conﬁrmed by demonstrating the ability
of 4P28ζN+, but not 4PTrN+, T cells to elicit cytotoxicity (Fig. 2d)
and release of interferon (IFN)-γ and tumor necrosis factor (TNF)-α
(Fig. 2e), when co-cultivated with PLP but not PL tumor cells. In our
in vivo model, P28ζ re-targeted CAR T cells elicited the complete
eradication of low burden PLP tumors that had been established for
7 days, whereas truncated CAR T cells were inactive (Fig. 2f).
Kinetics and impact of 99mTcO4− uptake transduced T cells.
Function of hNIS was demonstrated by in vitro 99mTcO4− uptake
by hNIS expressing T cells (Fig. 3a) and retroviral packaging cell
lines (Supplementary Fig. 1b). Uptake above background was
completely abrogated by addition of the competitive inhibitor,
sodium perchlorate (NaClO4−), further substantiating the role of
hNIS in this process (Fig. 3a and Supplementary Fig. 1b).
Importantly, 99mTcO4− uptake in the T cells did not affect via-
bility, indicated by their ability to proliferate after exposure to
isotope (Fig. 3b). Furthermore, 99mTcO4− uptake was only seen
in viable T cells, irrespective of transgene expression (Fig. 3c).
Saturation of relative activity was not reached in vitro over a 120-
min period (Fig. 3d). Increasing the concentration of 99mTcO4−
had minimal impact on relative levels of 99mTcO4− uptake
(Fig. 3e), and complete removal of radioactivity from the medium
showed rapid efﬂux with reestablishment of a steady state within
15 min (Fig. 3f).
In vivo validation of hNIS function in tumor free mice. Next,
we investigated if 4P28ζN+ T cells could be detected in vivo by
SPECT/CT imaging. Decreasing doses of 4P28ζN+ T cells, from
5 × 105 to 0.15 × 105 in six increments, were injected sub-
cutaneously in the tissue overlying the scapula in NSG mice.
SPECT/CT images were acquired after intravenous 99mTcO4−
injection via the tail vein. Percentage of the total injected dose,
corrected for thigh uptake to account for blood pooling, was
calculated for each individual 4P28ζN+ T-cell injection (Fig. 4a).
The highest recovered dose was seen at the highest (5.0 × 105)
dose (Fig. 4b). Even at the lowest dose of 15,000 4P28ζN+ T cells,
the subcutaneous localization of the hNIS expressing cells could
be clearly visualized (Fig. 4c) on whole animal SPECT/CT images.
Delineation of the speciﬁcity of the hNIS reporter was
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Fig. 1 Establishing a PSMA+/− xenograft model. a Representative ﬂow cytometry pseudo-color density plot of PL and PLP tumor cells to assess PSMA and
tdTomato expression. b In vitro growth of PL and PLP tumor cells. c In vivo growth of PL and PLP subcutaneous tumor xenografts was assessed using
bioluminescence imaging. Differences were not statistically signiﬁcant. d Representative ﬂow cytometry histograms of PL and PLP tumor cells to detect
hNIS expression on the cell surface. e Relative in vitro uptake levels of PL and PLP tumor cells treated with 0.1 MBq 99mTcO4− in the presence or absence
of 10mM NaClO4−. Empty RD packaging cells were used as a control. All graphs presents mean ± s.e.m. of three independent experiments
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demonstrated in vivo by the evaluation of signal when adminis-
tration of 99mTcO4− was preceded by either PBS or sodium
perchlorate (NaClO4−) in mice with high tumor burden xeno-
grafts (Fig. 4d,e). In the NaClO4− pre-treated animals, focal areas
of 99mTcO4− uptake (particularly in the thyroid and stomach)
were no longer seen with the total injected dose distributed
throughout the blood pool.
CAR T-cell imaging in a low tumor burden model. To further
investigate whether migration of 4P28ζN+ CAR T cells could be
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Fig. 2 Tri-cistronic retroviral vectors function. a Schematic diagram of the CAR constructs. b Representative ﬂow cytometry histograms of CAR, 4αβ chimeric
cytokine receptor and hNIS expression on the cell surface of transduced T cells. c Fluorescence quantitation of cell surface expression of IL-4Rα. n= 4 donors/
group. d Percentage cell viability of tumor cells 24 h after co-culture with T cells (1:1 E:T ratio) as determined by MTT assays. n= 4 donors/group. Graph
presents mean ± s.e.m. **P < 0.01, ***P < 0.001. Supernatants from the experiments in c were used in ELISAs to determine the levels of (e) IFN-γ and TNF-α
secretion by T cells. n= 4 donors/group. Graph presents mean ± s.e.m. ***P < 0.001. f Tumor burden of subcutaneous ﬁreﬂy luciferase-expressing PLP tumors
treated with 4P28ζN or 4PTrN was assessed by BLI over a period of 21 days. n= 3 animals/group. Graph presents individual animal BLI signals
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tracked in vivo by SPECT/CT imaging, low burden (7 day) PLP
tumors were established. Serial dual modality imaging was used
to monitor tumor growth (BLI) and intra-tumoral accumulation
of hNIS+ CAR T cells (SPECT/CT), according to the indicated
experimental plan (Supplementary Fig. 3a). Baseline SPECT/CT
images were acquired for normalization and showed no
99mTcO4− uptake within tumors above blood pool levels (Sup-
plementary Fig. 3b). In 4P28ζN-treated animals, tumor-derived
BLI signal plateaued from the day of T-cell administration,
sharply decreased from day 14 and became undetectable by day
21 (Fig. 5a and Supplementary Fig. 3c). SPECT/CT scanning
demonstrated that this therapeutic response correlated with focal
intra-tumoral uptake of 99mTcO4− by day 16 (day 9 post T-cell
injection) in two of the three 4P28ζN animals (Fig. 5b). This
activity was absent by day 21, at which time tumors had been
eradicated (Fig. 5b). Tomographic images are shown in Fig. 5c.
SPECT/CT imaging revealed intra-tumoral accumulation of T cells
at day 21 in one mouse treated with 4PTrN+ T cells (gray line;
Fig. 5c, d). While this was accompanied by a leveling off in the rate
of tumor progression (indicated by BLI signal), tumor control did
not occur (Fig. 5a, b) and all 4PTrN+ T-cell and PBS-treated
animals were culled owing to advanced tumor size at day 21.
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Fig. 3 Establishing and validating hNIS function. a Relative in vitro uptake levels of T cells treated with 99mTcO4− in the presence or absence of NaClO4−. n
= 3 donors/group. b Cell counts of untransduced or 4P28ζN T cells after 24 h culture in the presence or absence of 99mTcO4−. n= 4 donors/group. Graph
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Despite physiologic uptake of isotope by endogenous mouse NIS
(mNIS) in stomach, salivary glands and thyroid, resolution of
imaging of T-cell accumulation in the tumors was excellent,
particularly in whole-body videos, where the tumor localization of
CAR T cells is clear in the 4P28ζN-treated animal day 9 post T-
cell infusion (Movies 1–6), and derived still images (Fig. 5d).
Removal of mNIS-expressing organs was not required to visualize
intra-tumoral T-cell uptake in images. A repeat ‘low tumor
burden’ experiment was undertaken in which tumor control was
not observed in 4P28ζN-treated animals (Supplementary Fig. 4a).
Notably, the T-cell donor for this experiment was a signiﬁcant
outlier with an extremely high CD4+/CD8+ ratio (Supplementary
Fig. 2d), which may explain the lack of efﬁcacy. Importantly,
however, marked accumulation of 4P28ζN T cells was seen in
two of the three animals, albeit at the later time point of
14 days following administration of CAR T cells (Supplementary
Fig. 4b,c).
CAR T-cell imaging in a high tumor burden model. Next, we
investigated CAR T-cell accumulation using the ‘high tumor
burden’ model. A sub-optimal dose of 1 × 106 4P28ζN+ T cells
was administered to mice bearing 14− day established PL or PLP
tumors (experimental protocol; Supplementary Fig. 5a). As
expected, tumor control was not seen in any animal, owing to low
dose of T cells and larger tumor size (Fig. 6a, Supplementary
Fig. 5c and Supplementary Fig. 6a). Mean BLI signal in PLP
tumors at day 14 were higher in comparison to PL tumors.
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Nonetheless, mean BLI signal in PLP animals only increased
marginally in contrast to a marked increase in PL animals
(Fig. 6b). This deceleration of growth is consistent with sub-
therapeutic PSMA-dependent activity of 4P28ζN+ CAR T cells.
Pre-treatment baseline SPECT/CT images again showed no
additional accumulation of isotope in either xenograft, compared
to blood pool levels (Supplementary Fig. 6b). Detectable homing
of 4P28ζN T cells to PLP tumors occurred within 24 h of T-cell
inoculation, with progressive ampliﬁcation of this signal there-
after (Figs. 6c, d, 4c and Supplementary Fig. 6b,c). Indeed, two
days after T-cell administration, four PLP tumors demonstrated
focal T-cell accumulation but only one PL tumor (Fig. 6d and
Supplementary Fig. 6c). However, by day 21, PLP and PL mice
demonstrated focal 99mTcO4− uptake within tumors (Fig. 6d and
Supplementary Fig. 6c). Once again, the anatomical resolution of
T-cell localization in the tumor was noteworthy (Fig. 6d).
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Immunohistochemistry conﬁrms CAR T-cell localization to
tumor. Finally, staining of frozen sections of ‘high tumor burden’
xenografts for human CD3ζ was undertaken 2 and 7 days after
CAR T-cell or PBS injection. In keeping with the SPECT/CT data,
inﬁltration of 4P28ζN+ but not control 4PTrN+ T cells was
observed in PSMA-expressing PLP tumors (but not PL tumors)
by day 2. A delayed, non-antigen speciﬁc, inﬁltration of 4PTrN
cells in PL and PLP tumors was visible by day 7 (Supplementary
Fig. 7).
Discussion
These data demonstrate for the ﬁrst time that human CAR T cells
can be repeatedly imaged in vivo using a hNIS-based reporter
system. This allowed us to explore the inter-relationship between
intra-tumoral CAR T-cell accumulation and disease control.
Translational SPECT/CT imaging with the tracer 99mTcO4−
offers potential for excellent utility as a reporter system for cell
therapy studies for three key reasons. Firstly, imaging with
99mTcO4− is routinely undertaken in the clinic. Secondly, the
approach described here is inexpensive and is compatible with
both PET and SPECT/CT scanners, both of which are standard
items of equipment found in clinical nuclear medicine depart-
ments. Finally, the practical and straightforward nature of this
technology makes hNIS highly amenable to incorporation into
clinical CAR T-cell protocols.
In small animals, SPECT/CT delivers high levels of resolution.
In human imaging, SPECT offers moderately lower sensitivity
and spatial resolution than PET. In practice, this is not likely to be
an impediment to the use of this approach in the clinic and recent
advances in SPECT imaging technology affording gains in both
resolution and sensitivity are enabling quantitation with SPECT
as part of the clinical routine48. If greater resolution/sensitivity
proves necessary, it should be noted that hNIS is also compatible
with a growing range of PET tracers49, albeit at a far greater cost
to implement.
Organ-speciﬁc tracer uptake by hNIS in the stomach and
thyroid would limit the use of this approach to image T cells
directed against tumors in those anatomical regions. One
potential solution to address this entails the administration of a
radio-opaque substance orally, prior to imaging, to allow activity
blocking in the stomach. This could be accomplished using
clinically available agents such as barium sulfate50. Excretion of
free isotope via the kidneys, with accumulation in the bladder, is a
limitation of many clinically useful radiotracers. This could mask
uptake into CAR T cells in the anatomical area. One possible
solution to this would be urinary catheterization, or hydration
followed by urination just prior to administration of isotope, in
human studies. In practice, renal excretion of F-18-
ﬂuorodeoxyglucose (18F-FDG), a tracer widely used in the
clinic for PET imaging, does not diminish the clinical utility of
this imaging approach.
Early translation of novel CAR T-cell approaches in man must
focus on safe delivery, efﬁcient manufacturing and the demon-
stration of meaningful signals of efﬁcacy. Some clinical studies
involving CAR T-cell immunotherapy have indicated that severe
and occasionally fatal toxicity can result from this complex but
highly promising therapeutic strategy10,16,51. Cytokine release
syndrome (CRS) is a prevalent toxic event and in fact may
represent a crude biomarker of sustained tumor rejection. Neu-
rological toxicity is also emerging as a challenge in the CD19 CAR
T-cell protocols. The mechanism of this organ-speciﬁc toxicity
remains incompletely understood at the present time. In devel-
oping CAR T-cell immunotherapeutic approaches for solid
malignancies, identiﬁcation of tumor-speciﬁc targets or targets
that are only found on ‘expendable’ normal tissues (such as CD19
on B cells) remains a pressing challenge. Consequently, on-target,
off-tumor toxicity represents a major concern in the development
of these experimental therapies. Clinical experience indicates that
such events can be unanticipated prior to ﬁrst in man evaluation,
making careful clinical trial design and execution all the more
critical15,16. A further complexity in CAR T-cell clinical devel-
opment is the role of conditioning regimens that achieve lym-
phodepletion and thereby potentiate efﬁcacy of the CAR T-cell
product. These regimens can elicit signiﬁcant toxic effects in
patients, which can be challenging to differentiate from adverse
events that are attributable to the CAR T cells themselves. The
ability to rapidly and non-invasively determine the direct con-
tribution of the CAR T cells to an adverse event will empower
clinicians with a greater mechanistic understanding of these
increasing clinical occurrences. Moreover, such information
would enable the evidence-based deployment of targeted
approaches to toxicity reversal, thereby improving the safety of
early phase CAR T-cell development. In the event of long-term
persistence of CAR T cells, the system described here would also
render delayed toxic events amenable to investigation using a
straightforward imaging-based approach.
Together, these data demonstrate the utility of hNIS-based
CAR T-cell imaging at the translational interface. While use of
hNIS is limited by physiologic expression in the thyroid, salivary
glands and stomach, it is not expressed in hematopoietic cells,
which represents a key strength. Improved understanding of
clinically relevant anti-tumor activity is also likely to be gained by
implementation of the proposed approach in man. Notably, we
observed an oscillating pattern of T-cell accumulation in some
mice in which tumor rejection occurred. This mimics the pattern
that has previously been described when bulky tumors are
rejected in a T-cell receptor-dependent manner52. The technology
is unencumbered allowing clinical investigators freedom to
incorporate this system into the development of novel CAR T-cell
platforms. In short, the incorporation of hNIS into CAR-
encoding vector systems provides a non-invasive platform to
investigate the serial bio-distribution of these cells in patients.
This offers an unparalleled opportunity to correlate the anato-
mical location and number of CAR T cells throughout the body
with the occurrence of toxicity and the dynamic alterations that
occur within malignant deposits.
Methods
Recombinant DNA constructs. All recombinant DNA constructs were expressed
via the retroviral vector SFG. An optimized furin cleavage site (RRKR), SGSG
linker and T2A peptide47 were utilized to ensure stoichiometric expression of more
than one construct in the same open reading frame. Where necessary sequences
were ‘wobbled’ maximally to reduce the risk of vector instability. The J591 antibody
sequence (used to construct the PSMA-speciﬁc P28ζ CAR) was provided by Dr
Neil Bander (Cornell University, NY). The P28ζ CAR was co-expressed with the
4αβ chimeric cytokine receptor and hNIS (named 4P28ζN). A truncated CAR, in
which the signaling domains of CD28 and CD3ζ were removed (named 4PTrN),
was similarly co-expressed with 4αβ and hNIS. Human PSMA was synthesized as
an NcoI/XhoI fragment and cloned into SFG using those restriction sites. SFG-Luc-
RFP was generated as previously described53, required fragments for cloning were
synthesized by Genscript (Piscataway, NJ).
Cell lines. The 293VEC-RD114 retroviral packaging cell line was provided by Dr.
Manuel Caruso, Biovec Pharma, Québec, Canada. The PC3-LN3 cell line was
provided by Prof. Sue Eccles, Institute of Cancer Research, London. The H29
transient retroviral producer cell line was obtained from Dr. Michel Sadelain,
Memorial Sloan Kettering Cancer Center, USA.
All cell lines were propagated in DMEM (Life Technologies) supplemented with
10% FBS (Sigma-Aldrich). In addition, the media used for the H29 cell line was
supplemented with 1 mg puromycin (Thermo Fisher Scientiﬁc), 165 mg geneticin
(Thermo Fisher Scientiﬁc), and 1 mg tetracycline (Sigma-Aldrich), which were
removed prior to transfection.
All cell lines were screened regularly for mycoplasma contamination.
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Retroviral transduction of cells. Plasmids were transfected into the H29 transient
retroviral producer cell line using polyethylenemine (PEI; Sigma-Aldrich). Brieﬂy,
PEI and plasmid DNA were mixed at a 3:1 ratio in serum-free DMEM and
incubated for 15 min at room temperature. The mixture was then added to H29
cells, which were incubated at 37 °C, 5% CO2. Viral supernatants were collected 72
h post-transfection and were used to generate stable retroviral producing 293VEC-
RD114 cell lines as well as PSMA-expressing PC3-LN3 cells.
Human peripheral blood mononuclear cells were obtained from healthy
volunteers, after written informed consent, under approval of the Guy’s and St
Thomas’ Research Ethics Committee (reference 09/H0804/92). PBMCs were
isolated by low-density centrifugation on Ficoll Pacque (Sigma-Aldrich), activated
for 48 h with CD3/CD28-coated paramagnetic Dynabeads at a 3:1 bead:cell ratio
(Thermo Fisher Scientiﬁc), transduced by centrifugation on Retronectin (Takara)
coated plates, and cultured in 100 IU/ml IL-2 or 30 ng/ml IL-4 (Miltenyi Biotec).
Media and cytokines were replenished every 2 days. Transduced T cells were
propagated in RPMI 1640 (Life Technologies) supplemented with 10% AB serum
(Sigma-Aldrich)
All media were supplemented with 2 mmol/L L-glutamine (Life Technologies),
100 units/mL penicillin, and 100 μg/mL streptomycin (Life Technologies).
T-cell co-cultures. PC3-LN3 cell lines were seeded at 1 × 105 cells/well in 24-well
plates and incubated overnight at 37 °C, 5% CO2. T cells were added to the
monolayers at a 1:1 ratio (with no added cytokines) and the co-cultures were
incubated for 24 h at 37 °C, 5% CO2. Supernatants were collected at this point for
cytokine detection. T cells were aspirated and residual monolayers were carefully
washed with PBS. To quantify residual viable tumor cells, wells were incubated
with 250 μg 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT;
Sigma-Aldrich) in media for 2 h at 37 °C, 5% CO2. Formed purple formazan
crystals were then re-suspended in 300 μl DMSO. Absorbance was measured at
560 nm, and tumor cell viability was calculated ((absorbance of monolayer and T-
cell co-culture/absorbance of tumor monolayer alone)×100).
Enzyme-linked immunosorbent assays. Cytokine concentrations were measured
in T-cell culture supernatants by using Human IFN-gamma DuoSet ELISA and
Human TNF-alpha DuoSet ELISA (R&D Systems, Inc.), according to the manu-
facturer’s instructions.
Cell proliferation assays. PC3-LN3 cell lines were seeded at 1 × 105 cells/well in
six-well plates and incubated at 37 °C, 5% CO2. At the indicated times, cells were
trypsinized and counted with a hemocytometer using the Trypan Blue exclusion
method.
In vitro 99mTc-pertechnetate assays. 99mTcO4− used in all experiments was
provided by the Radiopharmacy, Nuclear Medicine Department, Barts Health NHS
Trust, London. The 99mTcO4− was eluted with saline from a generator, which had
been eluted in the last 24 h to minimize the build-up of 99Tc.
T cells at 1 × 106 cells/condition were treated with either PBS or 10 mM sodium
perchlorate (Sigma) and incubated for 30 min at 37 °C, 5% CO2. Cells were then
incubated with 0.1 MBq 99mTcO4− for 30 min at 37 °C, 5% CO2. Cells were washed
three times in ice-cold PBS before quantifying the remaining radioactivity using a
gamma counter (LKB Wallac 1282 Compugamma CS).
The viability of 99mTcO4−-treated T cells was determined by cell counts with a
hemocytometer using the Trypan Blue exclusion method. T cells were seeded at
1 × 106 cells/well in six-well plates and were treated with either PBS or 0.1 MBq
99mTcO4− and were incubated for 24 h (with no added cytokines) at 37 °C, 5% CO2
after which viability was determined.
Speciﬁc 99mTcO4− uptake in viable cells was determined by measuring the
radioactivity of the cells using a gamma counter. T cells at 1 × 106 cells/condition
were either left untreated or ﬁxed with 4% PFA for 15 min on ice, which was then
followed by incubation with 0.1 MBq 99mTcO4− for 30 min at 37 °C, 5% CO2. Cells
were washed three times in ice-cold PBS before quantifying the remaining
radioactivity.
To determine 99mTcO4− uptake at various concentrations, various activities of
99mTcO4− in 50 µl PBS were added to 450 µl of 5 × 105 transduced T cells kept at
37 °C in PBS in triplicate to give activity concentrations of 0.02, 0.2, 2, 5, 10 and 20
MBq/ml and incubated for 1 h (inverting every 5–10 min). Cells were centrifuged
and washed in ice-cold PBS twice before quantifying the cell-associated
radioactivity using a gamma counter. To determine 99mTcO4− uptake over time,
5 × 105 transduced T cells were cultured with 2MBq/ml 99mTcO4− (0.5 ml total
volume) and treated as above at 15, 30, 60 or 120 min in triplicate before counting
in a gamma counter. For efﬂux experiments 5 × 105 transduced T cells were
cultured in triplicate with 2MBq/ml 99mTcO4− for 1 h. Cells were centrifuged and
washed twice in ice-cold PBS then the radioactivity of the cells measured using a
gamma counter (time point 0) or resuspended in pre-warmed PBS and cultured for
15, 30, 60 or 120 min before centrifuging and washing twice with ice-cold PBS.
Cell-associated radioactivity was measured using a gamma counter.
Flow cytometry. Flow cytometry was performed on a BD-LSRII cytometer and
data analyzed with FlowJo software (TreeStar). Expression of the P28ζ CAR was
detected using the goat anti-mouse F(ab’)2 IgG RPE-conjugate at a concentration
of 10 μg/ml (Dako, 13416.1), which binds to murine sequences within the J591-
derived single chain antibody fragment. The following primary antibodies were
used: PSMA was detected using a mouse anti-human PSMA at a concentration of
10 μg/ml (MBL Life Science, K0142-3), a mouse anti-human CD124 at a con-
centration of 5 μg/ml (BD Biosciences, 552178) was used to detect the 4αβ chimeric
cytokine receptor, and a mouse anti-human NIS at a 1:50 dilution (Imanis Life
Sciences, REA003) was used to detect NIS on the cell surface. For immunophe-
notyping and determining the T-cell ratio, the following antibodies were used:
CD4−FITC (eBiosciences, 11-0048-41), CD4−APC (eBiosciences, 17-0048-41),
CD8-FITC (eBiosciences, 11-0089-42), CD45RO-PE (eBiosciences, 12-0457-42)
and CCR7-APC (eBiosciences, 17-1979-42) all at a concentration of 0.25 μg/test.
For ﬂuorescence quantitation of number of CAR constructs on the cell surface, the
Quantum R-PE MESF (Bangs Laboratories, Inc) kit was used as per the manu-
facturer’s instructions. The following secondary antibodies were used: goat anti-
mouse F(ab’)2 IgG RPE-conjugate at a concentration of 10 μg/ml (Dako, 13416.1)
and Afﬁnipure goat anti-mouse IgG (Fcγ fragment speciﬁc) Alexa Fluor 647-
conjugate at a 1:100 dilution (Jackson ImmunoResearch Laboratories Inc, 115-605-
008). Positive staining was assessed by comparison to the relevant isotype control
antibody and/or FMO.
Xenograft model and adoptive CAR T-cell therapy. Male NOD scid gamma
(NSG (JAX strain, NOD.Cg-Prkdcscidll2rgtm1Wjl/SzJ)) mice were used, age 6 weeks
to 8 weeks old (Charles River UK). This study was performed strictly adhering to
the UK Home Ofﬁce guidelines and licenses governing this work. Mice were
inoculated with 2.5 × 105 tumor cells in the right ﬂank. At the indicated time
points, mice received 1 × 106 CAR+ T cells intravenously. T cells were used at
12–14 days post-transduction.
Immunohistochemistry. Subcutaneous xenografts were established in NSG mice,
as described above, for 14 days. The mice then received 1 × 106 CAR+ T cells
intravenously. T cells were used at 12–14 days post-transduction. Tumors were
collected at the indicated time points and snap frozen in optimum cutting tem-
perature (O.C.T) embedding matrix (CellpathTM). Blocks were sectioned and
stored at −80 °C. Slides were thawed at room temperature for 5 min, ﬁxed in 10%
formalin for 15 min and washed in PBS. Slides were incubated with the primary
antibody, monoclonal rabbit anti-human CD3ζ (clone MRQ-39, OriGene), at a 1/
1000 dilution with DAKO diluent (Ely, Cambridgeshire, UK), for 1 h. Secondary
staining with the VECTASTAIN Elite ABC-HCP kit was undertaken according to
manufacturers instructions (Burlingame, California, USA). Slides were counter-
stained with Gills no 3 Haematoxylin, differentiated in 1% acid alcohol, dehydrated
and mounted.
In vivo blocking of 99mTcO4− uptake. Subcutaneous xenografts were established
in NSG mice, as described above, for 14 days. The mice then received 1 × 106 CAR
+ T cells intravenously. T cells were used at 12–14 days post-transduction. At day 7
post T-cell transfer and 30 min before 99mTcO4− infusion, the mice received either
an i.p injection of 500 μl PBS or sodium perchlorate (10 mg/ml in PBS). NSG mice
were then injected via the tail vein with 20MBq of 99mTcO4− 1 h prior to SPECT
imaging, which was performed using the methods described below.
Threshold determination in vivo. NSG mice were inoculated in the subcutaneous
space overlying the scapula with indicated doses of CAR+ T cells. T cells were used
at 12–14 days post-transduction. The mice were then subjected to SPECT/CT
imaging 1 h post T-cell inoculation, using the method described below.
In vivo Nano-SPECT/CT imaging. NSG mice were injected via the tail vein with
20MBq of 99mTcO4− 1 h prior to SPECT imaging. The mice were then anaes-
thetized with 2% isoﬂurane gas and 1 L/min oxygen and whole-body SPECT
images obtained using a NanoSPECT/CT four-head camera (Bioscan, Inc.,
Washington DC, USA) ﬁtted with 1.4 mm pinhole collimators in helical scanning
mode (24 projections, 40 min acquisition). CT images were acquired with a 45-kVP
X-ray source (1500 ms exposure, 180 projections). A multiple bed system was used
to allow three mice to be imaged simultaneously and body temperature was
maintained via a warm air heating system. CT reconstruction was undertaken with
InVivoScope (inviCRO LLC, Boston, USA) and SPECT reconstruction with HiS-
PECT, (Scivis GmbH, Göttingen, Germany) then merged and region of interest
analysis performed using VivoQuant software (inviCRO LLC, Boston, USA).
99mTc-pertechnetate uptake in the tumor was quantiﬁed with 3D ROI analysis.
The percentage injected dose was calculated (with decay correction), and
normalized to baseline SPECT values.
In vivo bioluminescence imaging. Bioluminescence imaging (BLI) was performed
at the indicated time points using an IVIS Lumina III in vivo imaging system
(PerkinElmer). Analysis was performed using Living Image 4.3.1 software (Caliper
Life Sciences). Mice underwent intraperitoneal injection with D-luciferin (150 mg/
kg; PerkinElmer) and were imaged under isoﬂurane anesthesia after 10 min. Image
acquisition was conducted on a 20 cm ﬁeld of view with medium binning for a
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range of exposure times (0.2–2 min). Animals were inspected daily and killed when
experimental endpoints had been achieved or when symptomatic due to tumor
progression. Tumor burden, as determined by IVIS imaging, was assessed using
region of interest (ROI) analysis. The resulting signal summations (total ﬂux in
units of photons/s) were plotted for each mouse.
Statistical analyses. All ﬁgures are representative of at least three independent
experiments unless otherwise noted. All graphs report mean ± s.e.m values of
biological replicates. Statistical signiﬁcance of the data was calculated using a
Student’s t-test. Signiﬁcance is designated with an asterisk in all ﬁgures (*P < 0.05,
**P < 0.01, and ***P < 0.001).
Data availability. The authors declare that all the data supporting the ﬁndings of
this study are available within the article and its supplementary information ﬁles
and from the corresponding author upon reasonable request.
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